DERMATOPHYTIC ONYCHOMYCOSIS TREATMENT MARKET ANALYSIS
Global Dermatophytic Onychomycosis Treatment Market: Key Developments
Key players in the market are focused on conducting clinical trials in order to expand their product portfolio. For instance, in December 2019, Moberg Pharma AB announced that MOB-015 (topical terbinafine) met both primary and key secondary endpoints of the clinical Phase 3 study that assessed the efficacy and safety of MOB-015 in patients with mild to moderate distal subungual onychomycosis.
Key players in the market are also focused on acquiring distribution rights of products to enhance their market share. For instance, in September 2018, Cipher Pharmaceuticals Inc. acquired the exclusive rights to commercialize, promote, sell, and distribute MOB-015 from Moberg Pharma in Canada for treatment of onychomycosis.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
